Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

NCT03542669 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Ovarian Carcinoma
Platinum-resistant Ovarian Cancer

Interventions

DRUG: 6B11-OCIK Injection
DRUG: Doxorubicin

Sponsor

Peking University People's Hospital

Collaborators

[object Object]